Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMP744 in Recurrent Glioblastoma
NCT07416188Phase 2Recruiting
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jul 2026
- Primary completion
- Dec 2030
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of LMP744 in glioblastoma (GBM), sponsored by National Institute of Neurological Disorders and Stroke. Started Jul 2026; status: recruiting.
02
Drugs
LMP744
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT07416188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416188.